How GLP-1s tanked and reshaped the medtech stock market | Mass Device
Promising clinical trial results on glucagon-like peptide 1 agonists (GLP-1s) created a seismic shift in the medtech stock market.Source: How GLP-1s tanked and reshaped the medtech stock market | Mass Device